Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company reported a revenue of 3.027 billion RMB in 2024, a year-on-year decrease of 24.09%, with a net profit attributable to shareholders of -287 million RMB, indicating a loss [2] - In Q4 2024, the revenue was 1.075 billion RMB, showing a quarter-on-quarter increase of 34.65% and a year-on-year increase of 21.83%, while the net profit was -84 million RMB [2] - For Q1 2025, the company achieved a revenue of 728 million RMB, a quarter-on-quarter decrease of 32.28% but a year-on-year increase of 141.32%, with a net profit of 73 million RMB, indicating a turnaround [2] Summary by Sections Revenue and Profitability - The company’s revenue for 2024 was 3.027 billion RMB, down from 3.988 billion RMB in 2023, with a projected recovery to 4.585 billion RMB in 2025, reflecting a growth rate of 51.45% [10] - The net profit is expected to improve from -287 million RMB in 2024 to 386 million RMB in 2025, with an EPS forecast of 0.363 RMB for 2025 [10] Market Dynamics - The prices of key products such as praseodymium-neodymium oxide and dysprosium oxide increased in Q1 2025, contributing to a significant rise in sales volume, which increased by 107.27% year-on-year in 2024 [3] - The company is expected to benefit from rising rare earth prices due to export controls and a tightening supply of overseas mines, alongside increasing demand from sectors like humanoid robots and low-altitude economy [4] Cost Management and R&D - The company maintained stable expense ratios, with a 31.91% decrease in period expenses in Q1 2025, while R&D expenses increased by 27.27% year-on-year [3] - The asset-liability ratio at the end of Q1 2025 was 7.64%, indicating ongoing optimization of the capital structure [3] Future Outlook - The completion of the 5000t/a rare earth separation processing project is expected to significantly enhance the company's operational performance in 2025 [4] - Revenue projections for 2025, 2026, and 2027 are 4.585 billion RMB, 5.929 billion RMB, and 7.387 billion RMB respectively, with corresponding net profits of 386 million RMB, 476 million RMB, and 648 million RMB [5]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company's Q1 2025 performance exceeded expectations, with revenue of 1.754 billion RMB, a quarter-on-quarter increase of 0.29% and a year-on-year increase of 14.19%. The net profit attributable to shareholders was 161 million RMB, reflecting a quarter-on-quarter increase of 70.48% and a year-on-year increase of 57.85% [2][3] - The prices of praseodymium and neodymium oxide and neodymium iron boron increased by 3.29% and 1.60% respectively, contributing to significant growth in sales volume, with a production of approximately 6,600 tons and sales of about 6,000 tons, both up over 40% year-on-year [3] - The company demonstrated effective cost control, with operating expenses decreasing by 10.97% quarter-on-quarter to 138 million RMB, while R&D expenses increased by 10.67% year-on-year to 83 million RMB [3] - The company announced a share buyback plan of 100 to 200 million RMB, indicating confidence in its future performance [3] Revenue and Profit Forecast - The company is projected to achieve revenues of 9.25 billion RMB, 11 billion RMB, and 14 billion RMB for the years 2025, 2026, and 2027 respectively, with net profits of 629 million RMB, 822 million RMB, and 1.221 billion RMB for the same years [5][10] - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 0.46 RMB, 0.60 RMB, and 0.89 RMB respectively, with corresponding price-to-earnings (P/E) ratios of 44.58, 34.13, and 22.98 [5][10] Market Conditions - The overall recovery of rare earth prices is anticipated to benefit the company, driven by export controls and a significant reduction in overseas mining supply, alongside a moderate increase in domestic mining quotas [4] - The demand for rare earth materials is expected to grow due to applications in humanoid robots and low-altitude economies, which may create new opportunities in the magnetic materials sector [4]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a significant price increase over the next 6-12 months [5]. Core Insights - In 2024, the company achieved a revenue of 1.222 billion RMB, representing a year-on-year growth of 20.98%, while maintaining the leading market share among domestic EDA companies. However, the net profit attributable to the parent company decreased by 45.46% to 109 million RMB [2]. - The company continues to expand its product matrix through self-research and mergers and acquisitions, launching new EDA tools that enhance simulation efficiency significantly [4]. - The company’s revenue projections for 2025 to 2027 are 1.661 billion RMB, 2.138 billion RMB, and 2.708 billion RMB, with expected growth rates of 35.91%, 28.68%, and 26.66% respectively [5]. Summary by Sections Performance Review - In Q4 2024, the company reported a revenue of 479 million RMB, a year-on-year increase of 29.13%, and a net profit of 51 million RMB, up 73.71% [2]. - The EDA software sales revenue for 2024 was 1.092 billion RMB, growing by 20.71%, while the technical services revenue reached 115 million RMB, increasing by 40.01% [3]. Business Analysis - The company’s gross margin for 2024 was 93.31%, a slight decrease of 0.48 percentage points from the previous year. The sales, management, and R&D expense ratios were 16.31%, 12.05%, and 60.79%, respectively, showing a decline compared to the previous year [3]. - The company’s overseas revenue accounted for 4.72% of total revenue, with a year-on-year decline of 13.32% [3]. Future Outlook - The company is expected to enhance its market share through strategic acquisitions, including the planned purchase of a semiconductor control company, which will provide comprehensive EDA solutions [4]. - The projected net profits for 2025, 2026, and 2027 are 158 million RMB, 218 million RMB, and 285 million RMB, respectively, with corresponding price-to-sales ratios of 39.67, 30.83, and 24.34 [5].

业绩简评 2025 年 4 月 25 日公司披露 24 年年报及 25 年一季报，2024 年公 司实现营收 272 亿元，同比下降 3.4%；实现归母净利润 3.46 亿 元，同比下降 8.1%。2025 年一季度公司实现收入 77.0 亿元，同 比增长 51.8%，实现归母净利润 3.0 亿元，同比下降 0.7%。 经营分析 风机制造及发电业务盈利承压，电站销售转让保持增长：2024 年 公司风机及相关配件销售实现收入 208.3 亿元，同比下降 12.4%， 实现毛利率-0.46%，同比下降 3.6%，预计主要受海风推进受阻， 交付不及预期影响，2025 年公司前期中标的广东多个重要海风项 目陆续开始施工，项目确收有望逐步加速。发电收入同比增长 15.4%，但毛利率同比下降 5.86pct 至 57.1%，预计主要受部分地 区新能源市场化交易推进，上网电价有一定下降影响。电站销售转 让保持增长，2024 年公司电站产品销售实现收入约 27.9 亿元，同 比+34.2%，毛利率同比提升 12.2pct 至 43.2%，同时实现投资收益 11.6 亿元，同比提升 38%。 Q1 交付加速，规模效应体现明显： ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [5][13]. Core Insights - In 2024, the company achieved a revenue of 1.222 billion RMB, representing a year-on-year growth of 20.98%, while maintaining the leading market share among domestic EDA companies. However, the net profit attributable to the parent company decreased by 45.46% to 109 million RMB, with a non-recurring net profit loss of 57 million RMB [2]. - The company continues to expand its product matrix through self-research and mergers and acquisitions, launching new EDA tools that enhance simulation efficiency significantly. The acquisition of a semiconductor control company is expected to improve the company's market coverage and share [4]. Summary by Sections Performance Review - In Q4 2024, the company reported a revenue of 479 million RMB, a year-on-year increase of 29.13%, and a net profit of 51 million RMB, up 73.71% year-on-year [2]. Operational Analysis - The EDA software sales revenue for 2024 was 1.092 billion RMB, growing by 20.71%, while the technical services revenue reached 115 million RMB, up 40.01%. However, hardware and other income fell by 35.71% to 15 million RMB. The overseas revenue accounted for 4.72% of total revenue, declining by 13.32% [3]. - The gross profit margin for 2024 was 93.31%, a slight decrease of 0.48 percentage points from the previous year. The sales, management, and R&D expense ratios were 16.31%, 12.05%, and 60.79%, respectively, showing a year-on-year decline [3]. Profit Forecast and Valuation - Revenue projections for 2025 to 2027 are 1.661 billion RMB, 2.138 billion RMB, and 2.708 billion RMB, with growth rates of 35.91%, 28.68%, and 26.66%, respectively. The net profit forecasts for the same period are 158 million RMB, 218 million RMB, and 285 million RMB, corresponding to price-to-sales ratios of 39.67, 30.83, and 24.34 [5][10].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company reported a revenue of 3.501 billion RMB in 2024, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 723 million RMB, up 27.2% year-on-year [2]. - The acquisition of Yingu Pharmaceutical for 704 million RMB is expected to enhance the company's growth potential by filling product gaps and improving sales capabilities [3]. - The orthopedic product segment continues to show robust growth, with revenue reaching approximately 2.32 billion RMB in 2024, a 9.5% increase year-on-year [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 1.021 billion RMB, reflecting a 12.3% year-on-year growth, and a net profit of 217 million RMB, up 13.9% year-on-year [2]. Operational Analysis - The orthopedic segment's revenue growth is attributed to an aging population and improved product margins, with a gross margin increase of 3.9 percentage points [3]. - The company plans to distribute a cash dividend of 0.90 RMB per share, totaling approximately 510 million RMB, which represents 70.64% of the net profit for 2024 [3]. Profit Forecast and Valuation - Revenue projections for 2025-2027 are estimated at 4.196 billion RMB, 4.683 billion RMB, and 5.231 billion RMB, with respective year-on-year growth rates of 19.9%, 11.6%, and 11.7% [4]. - The expected net profit for the same period is projected to be 840 million RMB, 950 million RMB, and 1.07 billion RMB, with growth rates of 15.9%, 13.1%, and 13.0% respectively [4].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company reported a revenue of 3.501 billion RMB in 2024, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 723 million RMB, up 27.2% year-on-year [2]. - The acquisition of Yingu Pharmaceutical for 704 million RMB is expected to enhance the company's growth potential by filling product gaps and improving sales capabilities [3]. - The orthopedic product segment continues to show robust growth, with revenues reaching approximately 2.32 billion RMB in 2024, a 9.5% increase year-on-year [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 1.021 billion RMB, reflecting a 12.3% year-on-year growth, and a net profit of 217 million RMB, up 13.9% year-on-year [2]. Operational Analysis - The orthopedic segment's revenue growth is attributed to an aging population and improved product margins, with a gross margin increase of 3.9 percentage points [3]. - The company plans to distribute a cash dividend of 0.90 RMB per share, totaling approximately 510 million RMB, which represents 70.64% of the net profit for 2024 [3]. Profit Forecast and Valuation - Revenue projections for 2025-2027 are estimated at 4.196 billion RMB, 4.683 billion RMB, and 5.231 billion RMB, with respective year-on-year growth rates of 19.9%, 11.6%, and 11.7% [4]. - The expected net profit for the same period is forecasted to be 840 million RMB, 950 million RMB, and 1.07 billion RMB, with growth rates of 15.9%, 13.1%, and 13.0% respectively [4].

Investment Rating - The report maintains a "Buy" rating for the company [4][9] Core Views - The company experienced short-term performance pressure but is actively expanding its overseas market, which is expected to create new growth points in the electric meter and energy storage businesses [2][3] - In 2024, the company achieved an operating income of 6.742 billion RMB, a year-on-year decrease of 1.89%, and a net profit attributable to shareholders of 753 million RMB, down 27% year-on-year [2][8] - The overseas revenue reached 1.126 billion RMB in 2024, marking a 34% year-on-year increase, indicating successful market expansion efforts [3] Summary by Sections Performance Overview - In 2024, the company reported an operating income of 6.742 billion RMB, a decrease of 1.89% from the previous year, and a net profit of 753 million RMB, down 27% year-on-year [2][8] - The first quarter of 2025 saw an operating income of 1.124 billion RMB, a 27% decline year-on-year, with a net profit of 124 million RMB, down 43% [2] Business Analysis - The company is focusing on overseas market expansion, with a significant partnership with global meter leader Landis+Gyr to increase market share in Western Europe and Asia-Pacific [3] - The energy storage segment generated 920 million RMB in revenue in 2024, a 39% decline, but maintained a gross margin of 17.64%, an increase of 1.55 percentage points year-on-year [3] - The company’s power station construction is progressing steadily, with power station revenue of 1.19 billion RMB in 2024, down 8%, but with a gross margin of 25.94%, up 14.46 percentage points year-on-year [3] Profit Forecast and Valuation - The projected net profits for 2025, 2026, and 2027 are 850 million RMB, 970 million RMB, and 1.1 billion RMB, respectively, with corresponding price-to-earnings ratios of 15, 13, and 12 times [4][8]

Investment Rating - The report maintains a "Buy" rating for the company [2][5] Core Views - The company reported a revenue of 831 million RMB for 2024, a decrease of 1.77% year-on-year, and a net profit attributable to shareholders of 144 million RMB, down 36.89% year-on-year. For Q1 2025, revenue was 239 million RMB, an increase of 8.85%, while net profit was 31 million RMB, down 26.99% year-on-year [2] - The company is experiencing a gradual recovery in operations, with revenue growth turning positive in Q4 2024 and Q1 2025. The company is strengthening its position in the outdoor equipment manufacturing sector while increasing investment in new product development [3] - The company is expanding its international market presence, having established partnerships with new brand clients in Australia and North America, with some products already in mass production [3] Summary by Sections Performance Review - For 2024, the company expects to distribute cash dividends of 67.53 million RMB, with a dividend payout ratio of approximately 52% [2] Operational Analysis - Revenue from tents, sleeping bags, clothing, and backpacks for 2024 was 361 million, 117 million, 256 million, and 39 million RMB respectively, with year-on-year changes of -22.33%, -2.29%, +41.73%, and -4.61% [3] - The company aims to deepen customer relationships and expand its high-potential customer base while introducing high-performance materials into its product lines [4] Financial Forecast and Valuation - The company is projected to have EPS of 2.36, 2.60, and 2.88 RMB for 2025-2027, corresponding to PE ratios of 15, 14, and 12 times [5] - The company’s revenue is expected to grow to 936 million RMB in 2025, with a growth rate of 12.68% [10]

Investment Rating - The report maintains a "Buy" rating for the company, with expected net profits for 2025-2027 projected at 458 million, 598 million, and 759 million RMB, representing year-on-year growth of 34%, 30%, and 27% respectively, corresponding to PE ratios of 36, 28, and 22 times [3][8]. Core Insights - The company's gross margin improved to 76.05% in Q1 2025, with a year-on-year increase of 1.44 percentage points and a quarter-on-quarter increase of 4.13 percentage points. The sales expense ratio decreased by 3.24 percentage points quarter-on-quarter to 52.17%, while the management expense ratio and R&D expense ratio saw slight reductions [3][8]. - The main brand, Marubi, continues to strengthen its market position in "eye care and wrinkle reduction," with a revenue of 2.055 billion RMB in 2024, a year-on-year increase of 31.69%, accounting for 69.24% of total revenue. The brand's flagship products have shown significant online sales growth [9][8]. - The PL brand, focusing on the base makeup segment, achieved a revenue of 905 million RMB in 2024, a year-on-year increase of 40.72%, contributing 30.51% to total revenue. Six foundation products exceeded 100 million RMB in annual GMV, indicating strong product performance [9][8]. Summary by Sections Financial Performance - The company reported a revenue of 2.226 billion RMB in 2023, with a growth rate of 28.52%. The projected revenue for 2024 is 2.970 billion RMB, with a growth rate of 33.44%. The net profit attributable to the parent company is expected to reach 342 million RMB in 2024, reflecting a growth rate of 31.69% [7][8]. - The diluted earnings per share are projected to increase from 0.647 RMB in 2023 to 1.143 RMB in 2025, with a corresponding increase in return on equity (ROE) from 7.75% in 2023 to 12.86% in 2025 [7][8]. Market Position - The report highlights the competitive landscape, noting that the main brand's growth has not met expectations due to intense online competition and slower-than-expected recovery in offline sales. However, the ongoing optimization of product structure and the deepening of the single product strategy are expected to drive future growth [3][8].